Video

Dr. Usmani on Treatment Considerations for Second Relapse Myeloma and Beyond

Saad Z. Usmani, MD, FACP, discusses treatment considerations for patients with multiple myeloma who are in their second relapse or beyond.

Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies at Levine Cancer Institute, Atrium Health, discusses treatment considerations for patients with multiple myeloma who are in their second relapse or beyond.

For patients who have relapsed 2 or more times, it is important to combine 2 therapies or mechanisms of action that the patient has not previously been exposed to, Usmani says. However, it is also possible to utilize at least 1 new mechanism of action in combination with another agent that the patient may have already been exposed to if it was not used during the previous relapse, he notes.

Currently, experts in the field are working to determine the best combination for this patient population. It is important to enroll patients on clinical trials with novel therapies, although there are other established options for patients with advanced multiple myeloma, Usmani explains. For example, belantamab mafodotin-blmf (Blenrep) was approved by the FDA in August 2020 for patients who are triple-class refractory. Additionally, selinexor (Xpovio) and dexamethasone are options for this patient population, Usmani says.

Additionally, melphalan flufenamide (Pepaxto), which was also approved by the FDA in February 2021 for select patients with relapsed and triple refractory multiple myeloma, is also an option, Usmani concludes.

Related Videos
Ashraf Z. Badros, MBCHB, professor, medicine, Medical Oncology, Hematology Oncology, University of Maryland Medical System
Binod Dhakal, MD
Michel Delforge, MD, PhD, professor, Faculty of Medicine, Department of Hematology, director, member, Leuven Cancer Institute, member, Senior Academic Staff, Council of the Faculty of Medicine, Council of the Department of Oncology, University Hospital Leuven, University of Leuven
Ajay K. Nooka, MD, MPH, FACP
Meletios A. Dimopoulos, MD
Binod Dhakal, MD
In this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil, discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the need for continued evaluation of prophylactic treatments like tocilizumab (Actemra) and antimicrobial measures for bispecific T-cell engagers, noting logistical and financial challenges and the importance of collaboration with community centers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil emphasize the need for comprehensive patient education, effective communication, and specific safety protocols to manage patients receiving bispecific T-cell engagers.
In this episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, Drs Usmani and Wasil discuss the challenges and strategies in managing bispecific T-cell engagers in the realm of cancer, emphasizing the importance of community and tertiary care collaboration to handle unique toxicities like cytokine release syndrome (CRS) and the need for well-defined protocols to ensure patient safety and effective treatment.